Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 131 to 140 of 544 total matches.
In Brief: Cardiovascular Outcomes with Bempedoic Acid (Nexletol)
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023 (Issue 1674)
– Esperion) in 2020,1
cardiovascular outcomes data in statin-intolerant
patients have become available ...
Since our initial review of the oral lipid-lowering
adenosine triphosphate-citrate lyase (ACL) inhibitor
bempedoic acid (Nexletol – Esperion) in 2020,
cardiovascular outcomes data in statin-intolerant
patients have become available.
Med Lett Drugs Ther. 2023 Apr 17;65(1674):62-3 doi:10.58347/tml.2023.1674b | Show Introduction Hide Introduction
In Brief: Dabrafenib (Tafinlar) and Trametinib (Mekinist) for Glioma (online only)
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023 (Issue 1674)
in patients ≥1 years old
who require systemic therapy.1,2 This combination is
the first systemic therapy ...
The oral kinase inhibitors dabrafenib (Tafinlar –
GSK) and trametinib (Mekinist – Novartis) have been
approved by the FDA for use together for a sixth
indication: treatment of low-grade glioma (LGG)
with a BRAF V600E mutation in patients ≥1 years old
who require systemic therapy. This combination is
the first systemic therapy to be approved in the US
for first-line treatment of LGG with a BRAF V600E
mutation in pediatric patients. The FDA also approved
new oral formulations of both drugs for patients
who are unable to swallow dabrafenib capsules or
trametinib...
Med Lett Drugs Ther. 2023 Apr 17;65(1674):e75-6 doi:10.58347/tml.2023.1674i | Show Introduction Hide Introduction
Risankizumab (Skyrizi) for Psoriasis
The Medical Letter on Drugs and Therapeutics • Jun 03, 2019 (Issue 1573)
.
The first year of treatment costs $88,500.
Its long-term safety is unknown.
Table 1. Pharmacology
Class ...
The FDA has approved the interleukin (IL)-23
antagonist risankizumab-rzaa (Skyrizi – Abbvie) for
treatment of moderate to severe plaque psoriasis in
adults. Risankizumab is the third IL-23 antagonist to
be approved for this indication; guselkumab (Tremfya)
and tildrakizumab (Ilumya) were approved earlier.
Anifrolumab (Saphnelo) for Systemic Lupus Erythematosus
The Medical Letter on Drugs and Therapeutics • Sep 20, 2021 (Issue 1633)
of anifrolumab was
based on the results of three 52-week, double-blind
trials (MUSE, TULIP-1, and TULIP-2 ...
The FDA has approved anifrolumab-fnia (Saphnelo – AstraZeneca), a type I interferon receptor antagonist, for IV treatment of adults with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard treatment. Anifrolumab has not been studied in patients with severe active lupus nephritis or severe active CNS lupus. It is the first type I interferon receptor antagonist to become available
in the US.
Toripalimab (Loqtorzi) for Nasopharyngeal Carcinoma (online only)
The Medical Letter on Drugs and Therapeutics • Jan 22, 2024 (Issue 1694)
Biosciences),
a programmed death receptor-1 (PD-1)-blocking
antibody, has been approved by the FDA for use ...
Toripalimab-tpzi (Loqtorzi – Coherus Biosciences),
a programmed death receptor-1 (PD-1)-blocking
antibody, has been approved by the FDA for use
in combination with cisplatin and gemcitabine for
first-line treatment of recurrent locally advanced or
metastatic nasopharyngeal carcinoma and for use as
monotherapy for treatment of recurrent unresectable
or metastatic nasopharyngeal carcinoma in adults
with disease progression on or after platinum-based
chemotherapy. It is the first immune checkpoint
inhibitor to be approved in the US for treatment of
nasopharyngeal carcinoma.
Med Lett Drugs Ther. 2024 Jan 22;66(1694):e16-7 doi:10.58347/tml.2024.1694e | Show Introduction Hide Introduction
Antibiotic Prophylaxis for Dental Procedures
The Medical Letter on Drugs and Therapeutics • Apr 29, 2024 (Issue 1701)
Antibiotic Prophylaxis for Dental Procedures
Volume 66 (Issue 1701) April 29, 2024
Table 1 ...
Since 2007, antimicrobial prophylaxis for dental
procedures has been recommended to prevent
viridans group streptococcal infective endocarditis
only for patients at highest risk of an adverse
outcome. Limiting use to such patients does not
appear to have led to an increased incidence of
infective endocarditis or increased mortality due to
infective endocarditis.
Med Lett Drugs Ther. 2024 Apr 29;66(1701):71-2 doi:10.58347/tml.2024.1701e | Show Introduction Hide Introduction
Metoclopramide Nasal Spray (Gimoti) for Diabetic Gastroparesis
The Medical Letter on Drugs and Therapeutics • Jan 11, 2021 (Issue 1615)
prolongation and cardiac
arrythmias.1,2 The macrolide antibiotics erythromycin
and azithromycin ...
The FDA has approved Gimoti (Evoke), a nasal
spray formulation of the dopamine-2 (D2) receptor
antagonist metoclopramide, for relief of symptoms in
adults with acute and recurrent diabetic gastroparesis.
Metoclopramide (Reglan, and generics) has been
available for years in conventional and orally-disintegrating
tablets and in an injectable formulation.
It is the only drug that is FDA-approved for treatment
of diabetic gastroparesis.
Cladribine (Mavenclad) for Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • Jul 29, 2019 (Issue 1577)
(PML)
compared to other MS treatments.1-3
Oral fingolimod (Gilenya), teriflunomide (Aubagio ...
The FDA has approved cladribine (Mavenclad – EMD
Serono), a purine antimetabolite, for oral treatment
of adults with relapsing forms of multiple sclerosis
(MS), including relapsing-remitting disease and
active secondary progressive MS (SPMS), who
cannot tolerate or have had an inadequate response
to other drugs indicated for treatment of MS. It is
not recommended for use in patients with clinically isolated syndrome (CIS). IV cladribine, which is FDA-approved
for treatment of hairy cell leukemia, has been
used off-label for treatment of MS.
Expanded Table: Some Drugs for Smoking Cessation (online only)
The Medical Letter on Drugs and Therapeutics • Jul 15, 2019 (Issue 1576)
)
Nicotine transdermal patch –
generic
NicoDerm CQ (GSK)
7, 14, 21 mg/24 hr
patches
1 patch/day ...
View the Expanded Table: Some Drugs for Smoking Cessation
Daprodustat (Jesduvroq) for Anemia of Chronic Kidney Disease
The Medical Letter on Drugs and Therapeutics • Feb 19, 2024 (Issue 1696)
expression. The drug mimics the effect
of hypoxia on stimulation of erythropoiesis.1
Table 1. Pharmacology ...
The FDA has approved daprodustat (Jesduvroq –
GSK), a hypoxia-inducible factor prolyl hydroxylase
inhibitor (HIF-PHI), for oral treatment of anemia due
to chronic kidney disease (CKD) in adults who have
been on dialysis for at least 4 months. It is the first
HIF-PHI and the first oral drug to be approved in the
US for this indication.
Med Lett Drugs Ther. 2024 Feb 19;66(1696):25-7 doi:10.58347/tml.2024.1696a | Show Introduction Hide Introduction